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Background: Cranberry fruits possess many biological activities partly due to their various phenolic compounds;
however the underlying modes of action are poorly understood. We studied the effect of cranberry fruit extracts on the
gene expression of Staphylococcus aureus to identify specific cellular processes involved in the antibacterial action.
Methods: Transcriptional profiles of four S. aureus strains grown in broth supplemented or not with 2 mg/ml of a
commercial cranberry preparation (NutricranW90) were compared using DNA arrays to reveal gene modulations
serving as markers for biological activity. Ethanol extracted pressed cakes from fresh fruits also produced various
fractions and their effects on marker genes were demonstrated by qPCR. Minimal inhibitory concentrations (MICs) of
the most effective cranberry fraction (FC111) were determined against multiple S. aureus strains and drug interactions
with β-lactam antibiotics were also evaluated. Incorporation assays with [3H]-radiolabeled precursors were performed
to evaluate the effect of FC111 on DNA, RNA, peptidoglycan (PG) and protein biosynthesis.
Results: Treatment of S. aureus with NutricranW90 or FC111 revealed a transcriptional signature typical of PG-acting
antibiotics (up-regulation of genes vraR/S, murZ, lytM, pbp2, sgtB, fmt). The effect of FC111 on PG was confirmed by
the marked inhibition of incorporation of D-[3H]alanine. The combination of β-lactams and FC111 in checkerboard
assays revealed a synergistic activity against S. aureus including strain MRSA COL, which showed a 512-fold drop of
amoxicillin MIC in the presence of FC111 at MIC/8. Finally, a therapeutic proof of concept was established in a
mouse mastitis model of infection. S. aureus-infected mammary glands were treated with amoxicillin, FC111 or a
combination of both; only the combination significantly reduced bacterial counts from infected glands (P<0.05)
compared to the untreated mice.
Conclusions: The cranberry fraction FC111 affects PG synthesis of S. aureus and acts in synergy with β-lactam
antibiotics. Such a fraction easily obtained from poorly exploited press-cake residues, may find interesting applications
in the agri-food sector and help reduce antibiotic usage in animal food production.
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Staphylococcus aureus is an opportunistic pathogen re-
sponsible for many infectious diseases in humans and ani-
mals [1]. This bacterium is among the most prevalent
causes of food poisoning gastroenteritis worldwide [2], as
well as a leading cause of intramammary infections (gland
inflammation, mastitis) in cows, milk quality and yield re-
duction, and major economic losses for the dairy industry
[3]. In poultry, S. aureus induces infections having a major
impact on the fertility and productivity of a breeder flock.
Infections by S. aureus can occur in the joints or as a gen-
eralized infection (septicemia). Manifestations with more
important economic consequences include synovitis with
arthritis, osteomyelitis, and dermatitis [4]. Early efficient
treatment of infection is paramount to avoid development
of a chronic infection, acute infection resulting in irrevers-
ible tissue necrosis, or exacerbation leading to organ failure
[5]. However, treating S. aureus infections becomes in-
creasingly challenging due to its capacity to develop en-
hanced antibiotic resistance. Such resistance has developed
due to the protective effects provided by biofilm produc-
tion [6], chromosomal mutations, the acquisition or ex-
pression of various antibiotic resistance genes including
those encoding low-affinity penicillin-binding proteins
(PBPs) involved in cell wall peptidoglycan biosynthesis, and
efflux pumps [7,8].
The first report of a penicillin-resistant S. aureus oc-
curred in the 1940s, followed by the emergence of
methicillin-resistant S. aureus (MRSA) strains, which pos-
sess the low-affinity PBP2A encoded by the mecA gene.
These now multi-resistant strains can induce various no-
socomial and community-associated infections [9]. The
emergence and widespread occurrence of hospital and
community acquired MRSA as well as livestock-associated
MRSA resulted from antibiotic selection pressure and hori-
zontal and vertical gene transfers [10]. Concerning live-
stock, a high prevalence of MRSA was reported in pigs and
pig farmers [11], and in Europe, MRSA strains found pri-
marily in pigs are now a leading cause of community-
associated MRSA infections in humans [12]. Similarly, the
recent emergence of bovine MRSA is also a concern since
these strains are transmittable to humans [13,14]. The oc-
currence of MRSA among companion and food-producing
animals and possible impact on human health has been
reviewed by Petinaki and Spiliopoulou [15]. New research
approaches, novel sources of antibiotic compounds and dis-
covery of original microbial cell targets need to be deve-
loped in order to overcome multi-resistant bacteria such
as MRSA.
The urge to bring forth novel antibiotic molecules has-
tened the investigation of the perspectives offered by
plants. As such, many studies on berry fruits have shown
the presence of large scale bioactive compounds such as
cancer cell growth inhibitors, antimicrobial molecules, andantioxidants [16-18]. Cranberry (Vaccinium macrocarpon
Ait) is one of the berries having the most potent antimicro-
bial effects against several human pathogens. We showed a
lower mortality rate in chickens fed a commercial cran-
berry fruit extract (NutricranW90) in feed compared to a
non-supplemented control diet and that feeding birds diets
containing cranberry fruit extract was effective in influen-
cing the populations of bacteria such as Enterococcus [19].
The mechanism underlining this observation is unknown,
however our study suggests that cranberry extract causes a
shift in the bacterial population in the intestinal tract.
Water-soluble phenolic compounds of cranberry juice,
such as flavonoids (ex: anthocyanins and flavonols), have
higher antimicrobial activities against foodborne patho-
gens than apolar phenolic compounds like polymeric tan-
nins [16]. The bacterial cell wall and cellular membranes
have been identified as targets of cranberry extracts on
Gram-negative and Gram-positive foodborne pathogens
like Escherichia coli O157:H7 and S. aureus [20], how-
ever, information is limited regarding the mechanism of
action of cranberry on bacteria.
In this work, we have investigated the effect of
NutricranW90, and three extracts obtained from fresh cran-
berry fruits, on the transcriptional profiles of S. aureus, to
provide insights on the antibacterial modes of action of
such preparations. We identified a transcriptional signa-
ture that reveals inhibition of bacterial peptidoglycan
biosynthesis. We also demonstrated the bactericidal
effect of a combination of a cranberry extract and
β-lactams in vitro, and the therapeutic usefulness of
such a synergistic combination of agents in a mouse
mastitis model of infection.
Methods
Bacterial strains and growth conditions
The antibiotic susceptibility testing reference strain
Staphylococcus aureus ATCC 29213, the sequenced
MRSA strains COL and N315, as well as the bovine mas-
titis isolates: Newbould (ATCC 29740), SHY97-4320 and
SHY97-3906, were used in this study. Strains SHY97-
4320 and SHY97-3906 were isolated from clinical mas-
titis and were previously described [21]. Bacteria stocks
were kept frozen at −80°C and grown on Mueller Hinton
agar or Cation adjusted Muller Hinton broth (CAMHB,
Becton Dickinson, Mississauga, ON, Canada). Viable
bacterial counts (CFU) were determined on Tryptic Soy
agar (TSA, Becton Dickinson).
Cranberry products, antibiotics and chemical reagents
A commercial cranberry product, NutricranW90 (NC90),
was obtained from Decas Botanical Synergies (Wareham,
MA, USA). The NC90 contained at least 88% carbohy-
drates, 30% organic acids, 2 to 3.8% total pheno-
lic compounds, 0.3 to 1% anthocyanins, 0.8 to 1.5%
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100% soluble in water as described by the manufacturer.
Laboratory and pilot-scale preparations of extracts were
performed with fresh Ben Lear cranberries obtained from a
local farm (Agassiz, British Columbia, Canada) or from
Ocean Spray (Langley, BC, Canada) as described previously
[17]. Chloramphenicol, oxacillin, amoxicillin, norfloxacin,
rifampicin and vancomycin were purchased from Sigma
Aldrich (Oakville, Ontario, Canada).
Preparation of cranberry press cake extracts
Laboratory-scale fraction were obtained from 2 Kg of fresh
fruits which were hammer milled through 1 cm holes then
pressed in a miniature rack and cloth press at 3000 psi for
10 min to obtain juice and press cake (PC). Triplicate allot-
ments of PC (90 ± 5 g) were placed into screw cap poly-
ethylene centrifuge containers and covered with 95%
ethanol and kept at room temperature for 48 h. Triplicate
extracts were pooled, dried by rotary evaporation to re-
move the ethanol (Büchi rotavapor R, Brinkmann Instru-
ments Canada Corp.; 30°C, speed 5–7, full vacuum
(−25kPa; Büchi Vac V-500) with condenser temperature of
0°C), and freeze dried (Virtis 50-SRC, Gardiner, NY, USA;
condenser at −56°C; vacuum at −100 milli-Torr; shelf at
25°C) to obtain fraction FC111. Replicate PC mashes were
used for one and two other extractions with 95% ethanol,
and the soluble fractions were freeze dried (fractions
FC121 and FC131, respectively). Pilot-scale extraction pro-
cedures were previously described [17]. In brief, the fresh
cranberries were pressed in a hydraulic rack and cloth
press and the juice was separated from the PC. Following
this step, the PC was covered with 95% ethanol for 24 h.
Then, the crushed cranberries were decanted and the sol-
uble fraction was refrigerated at 1°C (fraction FC111).
Phenolic acids, anthocyanins, flavonols and tartaric es-
ters were determined by the method of Oomah et al. [22].
Antioxidant activity was measured through oxygen radical
absorbance capacity (ORAC), as described previously [23].
The polyphenolics and antioxidant activities of the fresh
cranberry fruit fractions obtained by pilot-scale ethanol
extraction of the PC was previously reported [17]. As de-
scribed, PC extracts including FC111 showed three to four
times the phenolic acid, tartaric ester contents and anti-
oxidant activities, as well as five to 10 times the flavonols
and anthocyanins of their respective juice powders [17].
There was good similarity between the amounts of mea-
sured chemical constituents of laboratory- and pilot-scale
preparations, as well as their antimicrobial activity (see
result section).
Antibiotic susceptibility testing and synergy studies
Minimal inhibitory concentrations (MICs) of antibiotics
and cranberry extracts were determined by a broth
microdilution technique, following the recommendationsof the Clinical and Laboratory Standards Institute [24]. A
checkerboard protocol [25] was conducted by a broth
microdilution method similar to that used for standard
MIC determinations to evaluate the effect of varying con-
centrations of cranberry extracts on the activity of known
antibiotics against S. aureus strains. The fractional inhibi-
tory concentration (FIC) indices were calculated as follow:
FIC index = FICA + FICB = A/MICA+ B/MICB, where A
and B are MICs of compounds A and B in combination,
MICA and MICB are the MICs of compound A and com-
pound B alone and FICA and FICB are the FICs of com-
pound A and of compound B. Indifference for drug
interactions or an additive effect is demonstrated if the
FIC index is >0.5-4, a synergy if the FIC index is ≤ 0.5,
whereas an antagonistic effect is represented by a FIC
index of >4 [26].
Time-kill experiments
Time-kill experiments were performed to observe the bac-
tericidal effect (i.e., a 3 log10 reduction in CFU/mL) of
cranberry extracts alone or in combination with sub-
inhibitory concentrations (sub-MICs) of traditional
antibiotics. The CAMHB medium was inoculated with S.
aureus at ~105-106 CFU/mL and grown at 35°C, with shak-
ing (225 rpm) in the absence or presence of tested agents
at the specified concentrations (see the figure legends). At
several time points, bacteria were sampled, serially diluted
and plated on TSA for CFU determinations.
Transcriptional profiles
The modulation of transcriptional profiles of S. aureus
strains ATCC 29213, MRSA N315, SHY97-4320 and
SHY97-3406 by the cranberry product NC90 was first eval-
uated by exploratory transcriptional profiling experiments
using a sub-genomic array as described previously (in de-
tail) [27,28]. Bacteria (~107-108 CFU/mL) were exposed to
NC90 at the MIC (2 mg/mL) for 30 min in CAMHB. Cul-
ture samples (~108 cells) were treated with RNAprotect
(Qiagen, Mississauga, ON, Canada) for at least 10 min.
Bacterial pellets were then suspended in 100 μL of TE buf-
fer containing 200 μg/mL lysostaphin and incubated at
room temperature for 1 h. RNA was extracted using the
RNeasy Mini Kit and treated with the RNAse-free DNAse
set (Qiagen). Total RNA (2.5 μg) and 1 μL of the appropri-
ate RNA spike from Lucidea Universal Scorecard (GE
Healthcare Life Sciences, Baie D’Urfé, QC, Canada) was re-
verse transcribed using 5 μg of random hexamers, a dNTP
mix, 5-[3-aminoallyl]-2-dUTP and the Superscript II RT
(Invitrogen, Life Technologies Inc., Burlington, ON,
Canada). The amino-modified cDNA was purified and
labeled with NHS-Cy3 (untreated control) and -Cy5
(bioactive agent test) prior to hybridization on GAPS II
slides (Corning, NY, USA). The probes (200 pmol, ≥8% in-
corporation) were suspended in 18.5 μL of hybridization
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mouse COT1 DNA (Invitrogen)). The prehybridization,
hybridization and washing steps were done as prescribed
for Corning Gaps II Slides. Hybridization signals for each
spot were quantified with the ScanArrayExpress Micro-
array Scanner and the ScanArrayExpress software V
2.2.0.0022 (Perkin Elmer, Wellesley, MA, USA). Inten-
sity of each dye was adjusted using the signal of the
control spots from Lucidea Universal Scorecard and
data were submitted to the Lowess normalization.
Only signals showing intensity three times above the
background were analyzed as described previously
[18,27]. Expression ratios (Cy5 [treated]/Cy3 [untreated
control]) were represented in log2. Only log2 ratios
with a minimum mean of ≥2.0 (or ≤ −2.0) obtained for
at least two of the four S. aureus strains tested were
considered. Data represent the average of triplicate
spots from duplicate independent experiments for each
of the four tested S. aureus strains. The modulation of
expression of marker genes providing transcriptional
signatures was thereafter confirmed by qPCR analyses.Quantitative PCR (qPCR)
Transcriptional modulations induced by cranberry frac-
tions and observed by using exploratory microarrays were
confirmed by qPCR for a selection of marker genes and
strains. Additional RNAs, from three independent bacte-
rial cultures and prepared as described above, were
obtained for qPCR analyses. The qPCR assays using SYBR
green (Invitrogen) and the JumpStart Taq DNA Polymer-
ase (Sigma) were performed as described previously [27]
for the marker vraS, sgtB, murZ, mrsA, lytM and mntB
genes indicative of a cell wall stress [29,30]. The relative
expression ratios were calculated using the cycle threshold
(Ct) of the untreated culture (no-bioactive agent control)
and that of the housekeeping gyrA gene [n-fold expres-
sion = 2-ΔΔCt, where ΔΔCt = ΔCt (treated culture)/ΔCt
(untreated culture) and ΔCt represents the difference be-
tween the Ct of the gene studied and the Ct of gyrA]. The
sequences of primers for qPCR were: gyrA-forward 50-
CATTGCCAGATGTTCGTGAC -30 and gyrA-reverse 50-
CACCAACGATACGTGCTGAT -30; vraR-forward AAA
AGATATCGCCGATGCAG and vraR-reverse ATAACT
CTGCCGCGCTTTTTC; sgtB-forward AAACCGCCGA
AAAAGAAAAA and sgtB-reverse TCATCCACATTATCG
CGTGT; msrA-forward GCAAATGGTGTAGGTAAGA
CAACT and msrA-reverse ATCATGTGATGTAAACA
AAAT; murZ-forward ACGCACACTAAATGGGGAAG
and murZ-reverse CCTCAGCAATTAAACCAGCA; lytM-
forward ATTAACAGCAGCAGCGATTG and lytM-re-
verse TGTGCTTGTTGGGTGTTTGT; mntB-forward C
CTGGTGTTGCCCTATCATT and mntB-reverse GGCG
TCAGGTTTCGTTTTAC.Inhibition of macromolecular biosynthesis
Macromolecular biosynthesis assays were performed
exactly as described previously [31]. Briefly, S. aureus
ATCC 292123 was grown in a complete defined medium,
and transferred to a round-bottom microwell plate con-
taining radiolabeled precursors [3H]-Leucine; [3H]-Thy-
mine; [3H]-Uridine (Perkin Elmer, Montreal, QC, Canada)
or D-[3H]-Alanine (American radiolabeled chemicals,
St-Louis, MO, USA), as well as various dilutions of anti-
biotic agents. Incorporation was allowed to proceed for 45
min (for Leu and D-Ala), or 35 min (for Thy and Uri)
at 35°C. The reaction was terminated by transferring the
mixtures into pre-chilled trichloroacetic acid (10% final),
followed by collection of the precipitated macromolecules
on GF/C filter using a dot-blot filtration system. The dri-
ed filter was cut and the level of radiolabeled precursor
incorporation was determined by liquid scintillation co-
unting. Data represent the average of three indepen-
dent experiments.
Mouse mastitis model of infection
The mastitis model was previously optimized for experi-
mental therapy [32]. CD-1 lactating mice (Charles River,
St-Constant, Canada) were used 12 to 14 days after off-
spring birth. Pups were removed 1 h before intramammary
inoculation, under anesthesia, of both L4 (on the left) and
R4 (on the right) abdominal mammary glands with 100 μL
of S. aureus Newbould (1 CFU/μL). Glands were treated
(intramammary) 4 h after infections with amoxicillin, a
cranberry extract or a combination of both. Mice were
then sacrificed 14 h post-treatment for mammary gland
sampling, homogenization, plating, and bacterial counts.
Data represent two independent experiments using several
mice and glands in each.
The animal experiments were conducted following the
guidelines of the Canadian Council on Animal Care. Proto-
col 08-FM1 was specifically approved by the institutional
ethics committee on animal experimentation of the Faculté
des Sciences of Université de Sherbrooke to perform the ani-
mal studies included in the present article.
HPLC-MS analysis of cranberry fraction FC111
One milligram aliquots of each dry powdered fraction
were suspended in 20% aqueous methanol, 0.1% TFA, at
1 mg/mL, prior to HPLC-MS analysis. This analysis was
performed on an Agilent 1100 series LC/MSD SL system
(Agilent Technologies, Mississauga, ON), equipped with a
quaternary pump, in-line degasser, robotic auto sampler
and diode array (DAD) and single quadropole mass spec-
trometry (SQD) detectors. The separation and character-
izations were achieved using a Zorbax Eclipse XDB-C18
(Agilent Technologies) analytical column (4.6 × 150 mm,
5 μm particle size) fitted with a Zorbax Eclipse XDB-C18
analytical guard column (4.6 × 12.5 mm, 5 μm particle
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ous trifluoroacetic acid; B = water:methanol:trifluoroacetic
acid 1:1:0.1; C = acetonitrile), at a flow rate of 0.5 mL/min,
with a column temperature of 45°C, and 15 μL sample
injection volume , according to the following gradient:
Time = 0 min. A:B = 100:0; Time = 2 min. A:B = 85:15;
Time = 20 min. A:B = 0:100; Time = 26 min. B = 100%
isocratic; Time = 30 min. B:C = 0:100; Time = 33 min.
C = 100% isocratic; post time equilibration (3 min.) A =
100%. The entire UV–vis absorption spectrum (190–900
nm) was recorded, while general phenolics (280 nm), an-
thocyanins (520 nm), and flavonols (360 nm) channels
were monitored. Atmospheric pressure electrospray io-
nization mass spectra in both positive (PIM) and negative
(NIM) ion modes (PIM = 150–1400 amu; NIM = 150–
2000 amu) were recorded on duplicate injections of the
same sample (drying gas flow 10 L/min; nebulizer pres-
sure 30 psig; dry gas temperature 350°C; PIM capillary
voltage 3000; NIM capillary voltage 3500). Peak identities
were assigned using a combination of UV–vis absorption
spectra, MS fragmentation patterns, congruent retention
times with commercially available standards, and compari-
son to relevant cranberry literature [33-35].Statistical analysis
Statistical analyses were carried out with the GraphPad
Prism Software (v.5.00). Tests used for the analysis of
each experiment are specified in the figure legends.Results
The NC90 and the PC fraction FC111 are bactericidal and
affect the transcription of genes associated with a cell
wall stress
The MIC of the cranberry product NC90 against S. aureus
ATCC 29213, Newbould and MRSA COL was 2 mg/mL.
In an attempt to understand the basis of the growth inhibi-
tory effect of NC90 observed on S. aureus, we studied the
modulation of bacterial gene expression for a variety of
strains by microarray analyses (Table 1). Exposure of any of
the four tested S. aureus strains (ATCC 29213, MRSA
N315, SHY97-4320, SHY97-3906) to NC90 up-regulated
strongly several genes involved in cell wall biosynthesis,
similar to the up-regulation of genes caused by antibiotics
known to disrupt peptidoglycan biosynthesis. Indeed, the
strong expression of fmt, pbp2, murZ, sgtB, tcaA and vraS/
R genes is evidence of a cell wall stress induced by the
tested cranberry product NC90 (Table 1). Our data are
consistent with the results from other laboratories on the
transcriptional profiles obtained by exposure of S. aureus
to oxacillin, bacitracin and D-cycloserine [30] or to dapto-
mycin and vancomycin [29] and these similarities are al-
so reported in Table 1. NC90 also up-regulated lytM,
encoding a peptidoglycan hydrolase distinctively likedaptomycin (Table 1), and down-regulated genes
such as spa, mntABC, isdA, hla, and femC.
To follow up, extracts from press cakes (PC) were investi-
gated. The MIC of FC111 (lab- and pilot scale extracts) was
lower than that of NC90 and represented 1 mg/mL against
S. aureus ATCC 29213, Newbould and MRSA COL. Be-
sides, the MIC value for both FC121 and FC131 was higher
(3 mg/mL). Since FC111 showed the lowest MIC (best effi-
ciency), its bactericidal effect against S. aureus ATCC
29213 and MRSA COL was evaluated in time-kill experi-
ments. FC111 at 1 mg/mL (MIC) induced more than a
3-log10 reduction of CFU/mL against both strains com-
pared to their respective untreated control cultures after
8 h of incubation and a concentration of 2 X MIC (2 mg/
mL) yielded more than a 6-log10 reduction of CFU/mL at
8 h and no detectable CFU after 24 h (data not shown).
Subsequently, we used qPCR to first confirm the tran-
scriptional effects induced in S. aureus ATCC 29213 fol-
lowing exposure to NC90 in DNA array experiments
(above) and secondly, to detect similar transcriptional
modulations induced by the most active ethanol-extracted
PC fraction FC111. Modulation of the same cell wall stress
markers (lytM, vraR, sgtB, msrA, murZ and mntB) was in-
deed detected for both FC111 and NC90, indicating a simi-
lar mode of action against S. aureus (Figure 1).
FC111 inhibits cell wall biosynthesis
Whole-cell macromolecular biosynthesis assays were per-
formed to elucidate the mechanism of action of FC111 and
to confirm its inhibitory effect on cell-wall biosynthesis.
S. aureus ATCC 29213 was treated with several concentra-
tions of the cranberry fraction FC111 or known antibiotics
and the percentage of incorporation of radiolabeled precur-
sors into macromolecules was evaluated (Figure 2). All
known drugs targeted the expected macromolecular bio-
synthesis; chloramphenicol, norfloxacin, rifampicin and
vancomycin inhibited protein, DNA, RNA and cell wall
biosynthesis, respectively. In the presence of 2 (2 mg/ml)
and 4 times (4 mg/ml) the MIC of the cranberry frac-
tion FC111, the incorporation of D-[3H]Ala, a pre-
cursor of cell wall peptidoglycan, was significantly
reduced compared to that observed for precursors of
DNA, RNA and proteins (Figure 2E).
In Vitro bactericidal effect of FC111 and β-lactam
antibiotic combinations
Since exposure of S. aureus to FC111 induced cell wall
stress, we investigated the potential synergy between this
cranberry PC fraction with amoxicillin (used for treatment
of S. aureus-induced bovine mastitis in veterinary medi-
cine) and oxacillin (used for many clinical indications in
humans). Checkerboard assays were performed and a FIC
index was determined for each tested combination against
S. aureus ATCC 29213 (β-lactam susceptible strain) and
Table 1 Genes up- and down-regulated for at least two of four S. aureus strains following a 30-min exposure to the














DAPb VANb OXAb OBCc Vrad
Up-regulated genes
0263 Peptidoglycan hydrolase 15.0 24.5 3.6 9.8 + = = =
1066 fmt Fmt protein 6.8 3.8 2.9 2.0 + + + + +
1459 Methionine sulfoxide reductase 2.3 6.0 −1.5 1.2 = + + +
1490 pbp2 Penicillin binding protein 2 2.5 2.8 1.0 1.9 + + + + +
1777 htrA Putative serine protease Htra 4.6 8.9 1.0 2.1 + + + =
1932 Transglycosylase domain protein 8.5 6.8 2.2 2.5 + = = + +
1942 vraR DNA-binding response regulator 8.8 10.9 nd 2.7 + + + = +
1943 vraS Sensor histidine kinase VraS 14.2 10.5 7.6 4.0 + + + + +
1944 Hypothetical protein 5.1 7.5 1.3 1.4 + + + + +
2017 groES Chaperonin nd 2.2 2.3 2.2 + + + =
2116 murAB UDP-N-AcGlc-1-carbotransferase 4.0 7.6 2.5 2.6 + + + + +
2291 Staphyloxanthin biosynthesis 6.0 2.2 4.5 3.9 – – – =
2352 tcaA TcaA protein 5.1 6.3 1.1 1.4 + + + + +
2584 isaA Immunodominant antigen A 2.1 1.8 2.3 2.1 = = = =
Down-regulated genes
0095 spa IgG binding protein −33.3 −2.0 −37.5 nd – = =
0096 sarS Accessory regulator −2.0 −2.9 −2.7 −2.2 – – –
0136-0150e capA-O Capsular polysaccharide −4.9 nd −3.1 −1.9 – = –
0317 Lipase precursor −8.6 −6.8 −4.1 −1.7 – – =
451-452e ahpFC Alkyl hydroperoxide reductase −3.4 −3.6 −8.2 −1.2 = = –
0679 Na+/H+ antiporter, MnhA −4.5 −10.0 −13.0 −25.0 = = =
0688-0690e mntABC ABC transporter −43.5 −66.7 −86.7 −91.7 – = =
0765-0766e saeSR Sensor/Histidine kinase −1.5 −3.7 −1.5 −3.6 = = =
1072 folD THF dehydrogenase −2.1 −2.6 −2.7 nd = = =
1079 purF amidophosphoribosyltransferase nd −10.0 −0.8 −2.6 = – –
1140 isdA Heme-iron transport −5.3 −2.1 −2.9 nd – = =
1158-1160e sdhABC Succinate dehydrogenase −5.1 −7.9 −4.5 −3.8 – – =
1173 hla Alpha-hemolysin −3.6 −4.3 nd −2.6 – = =
1262-1263e sucCD Succinyl-CoA synthetase −5.6 −3.1 −6.4 −2.3 = = =
1328 glnR Glutamine synthetase repressor −3.7 −6.3 −3.4 −5.3 – – =
1329 femC Glutamine synthetase FemC −2.7 −4.2 −3.2 −2.9 – = =
1368 katA Catalase −3.2 −2.4 −5.2 −2.1 = + =
1385 acnA Aconitate hydratase −3.4 −3.0 −6.3 nd = = =
1396 fmtC FmtC protein −0.9 −2.4 −2.0 nd – – –
1448-1449e sucAB 2-oxoglutarate dehydrogenase −8.1 −5.4 −4.8 −4.9 = = =
1741 icd Isocitrate dehydrogenase, NADP −5.6 −2.2 −11.5 −2.5 = = +
1742 gtlA Citrate synthase −6.7 −2.3 −14.3 −2.2 = = +
1743 Amino acid permease −3.1 −1.2 −4.8 −1.5 = = =
2055 rsbW Anti-sigma B factor −2.6 nd −1.6 −2.1 – = –
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Table 1 Genes up- and down-regulated for at least two of four S. aureus strains following a 30-min exposure to the
cranberry product NC90 (2 mg/mL) (Continued)
2057 rsbU Sigma factor B regulator protein −1.3 −3.1 −0.9 −2.1 = = –
2066-2068e kdpABC Potassium-transporting ATPase −3.5 nd −2.3 −1.7 = = =
2293 NAD/NADP dehydrogenase −2.0 −2.4 −1.3 nd – = –
2694 geh lipase −27.3 −4.3 −20.0 nd = = =
a Data are expressed in log2 ratios of Cy5(cranberry-treated)/Cy3(untreated control); see material and methods.
b Up (+) or down (−) expression of the indicated gene by exposure to daptomycin (DAP), vancomycin (VAN) or oxacillin (OXA), as reported by Muthaiyan et al.
[29]; the equal sign (=) indicates genes that were not affected.
c Up (+) or down (−) expression of the indicated gene by exposure to oxacillin (O), bacitracin (B) and D-cycloserine (C) as reported by Utaida et al. [30]; the equal
sign (=) indicates genes that were not affected.
d The plus sign (+) indicates genes known to be regulated by the two-component response regulator VraSR following a cell wall stress [42].
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sistance). The cranberry fraction FC111 increased the in-
hibitory activity of amoxicillin and oxacillin against both
tested S. aureus strains by triggering up to 512-fold reduc-
tions in β-lactam MIC values (Table 2). Combination of
FC111, 128 or 256 μg/mL (i.e., 1/8 or 1/4 FC111 MIC, re-
spectively), with either of the β-lactams yielded FIC indices
of ≤0.25, for each of the strains tested. These FIC indices
clearly showed synergy between FC111 and β-lactams
against S. aureus. Data also demonstrated that this synergy
can efficiently bypass the mecA-mediated mechanism of
β-lactam resistance found in MRSA strain COL.
The synergistic effect arising from the combination of
β-lactams and FC111 in checkerboard assays was ex-
plored in greater details by using kill kinetic studies.
Combination of the cranberry fraction FC111 at its MIC
(1 mg/mL) and 1/8 × MIC of amoxicillin induced a
strong bactericidal effect (>3 Log10 CFU/mL) against a
bovine mastitis strain (S. aureus Newbould, also used in
our mastitis model of infection in the mouse [see below])
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Figure 1 qPCR analysis of transcriptional modulations induced






























Figure 2 Comparison of the inhibitory effect of a variety of
molecules on macromolecular biosyntheses in S. aureus ATCC
29213. Chloramphenicol (Panel A, CHL), norfloxacin (Panel B, NOR),
rifampicin (Panel C, RIF), vancomycin (Panel D, VAN), and the
cranberry fraction FC111 (Panel E). For A-D, a one-way analysis of
variance (ANOVA) with Dunnett’s post test was performed where
the macromolecule’s biosynthesis associated to the test antibiotic
served as comparator for the three others (*, P <0.05; ***, P<0.001).
In E, a two-way ANOVA with Bonferroni’s post test was performed
(*, P<0.05; **, P<0.01).
Table 2 Minimal inhibitory concentrations (MIC) of amoxicillin and oxacillin alone or in combination with increasing
concentrations (0 to 256 μg/ml) of the cranberry PC fraction FC111 against S. aureus ATCC 29213 and MRSA COL
S. aureus strains Antibiotic MIC of antibiotic in μg/mL in the presence of an increasing concentration of the cranberry fraction FC111,
also in μg/mL (fold decrease in antibiotic MIC)a
0 32 64 128 256
ATCC 29213 amoxicillin 0.06 0.06 (1×) 0.06 (1×) 0.015 (4×) 0.015 (4×)
MRSA COL 512 4 (128×) 4 (128×) 1 (512×) 1 (512×)
ATCC 29213 oxacillin 0.5 0.06 (8×) 0.03 (16×) 0.03 (16×) 0.03 (16×)
MRSA COL 512 256 (2×) 128 (4×) 32 (16×) 16 (32×)
a Combination of 128 or 256 μg/mL of FC111 with either antibiotic yielded FIC indices of ≤0.25 against all tested strains.
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http://www.biomedcentral.com/1472-6882/13/90or amoxicillin alone (Figure 3A). Moreover, the combin-
ation of FC111 at its MIC and oxacillin (1/512 × MIC)
also showed strong bactericidal effect against S. aureus
MRSA COL (Figure 3B).
The FC111-amoxicillin combination improves bacterial
clearance in mammary glands
The in vivo relevance of the synergy between the cranberry
extract FC111 with β-lactams was determined using a
mouse mastitis model. The mice were infected with the
bovine strain S. aureus Newbould and treated with FC111,
amoxicillin or a combination of both (Figure 4). Compared
to the untreated mice, there was no significant change in
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Figure 3 S. aureus kill-curve kinetics evaluated in cation-adjusted Mu
the specified antibiotic. Panel A, FC111 alone (at its MIC, 1 mg/mL) or in
aureus strain Newbould, and Panel B, with a sub-MIC (1/512 x MIC) of oxac
experiments. Bars represent standard deviations (SD).with either one of the compounds. However, a significant
reduction in bacterial counts (1.8 Log10 CFU/g of gland)
was observed using the FC111-amoxicillin combination.
HPLC-MS analysis of cranberry fraction FC111
HPLC-MS was performed on laboratory-scale cranberry
fraction FC111, which had the following spectrophotomet-
rically measured [22] classes of chemical compounds per
gram of freeze-dried powder: 132.4 (total phenolics), 8.3
(tartaric esters), 9.6 (flavonols) and 23.8 (anthocyanins)
mg equivalents of catechin, caffeic acid, quercetin and
cyanidin-3-glucoside, respectively. The total phenolics, tar-
taric esters and flavonols compared well with the compos-
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OXA (1/512 x MIC) + FC111 (MIC)
FC111 (MIC)
Strain MRSA COL
eller Hinton broth containing FC111 alone or in combination with
combination with a sub-MIC (1/8 x MIC) of amoxicillin against S.














































Figure 4 Bacterial counts (CFU) obtained from mice mammary
glands 10h post-infection with S. aureus. Mice mammary glands
were treated (intra-mammary administration) 4h after infection with
PBS with or without amoxicillin (AMO), the cranberry fraction FC111
(FC) or a combination of both at the indicated concentration
(mg/mL). Each dot represents the CFU of each individual gland
(n= 6–8) and the median value for each group is indicated by
the bar. Statistical differences (P<0.05) between CFU recovered
from treated and untreated animals are shown (non-parametric











































Figure 5 C18 reversed-phase HPLC chromatogram of laboratory scale
Retention time is in minutes, and absorbance measured at 254 nm (mAU).
summarized in Table 3.
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http://www.biomedcentral.com/1472-6882/13/90pilot-scale prepared FC111 provided identical antibacterial
activity against S. aureus strains as reported above. HPLC
separation of cranberry fraction FC111 constituents was
achieved in less than 30 min, using the program de-
scribed above. A typical chromatographic trace, recorded
at 254 nm from laboratory scale FC111 (Figure 5), dem-
onstrates the separation of iridoids, hydroxybenzoic acid,
hydroxycinnamic acid, anthocyanin and flavonol compo-
nents (Table 3). Compounds lacking UV-absorbing chro-
mophores (sugars, small organic acids etc.) were omitted
from analysis. In fraction FC111, qualitatively representa-
tive of all PC extracts, the principal components were an-
thocyanins, peaks 21, 24–29, 31, 33 (40%), flavonols,
peaks 30–32, 34–44 (25%), iridoids, peaks 2a,b, 3, 16b
(22%), and the conjugated glycosides of simple phenolic
acids, peaks 4–15, 16a, 17–19 (9%), based on integrated
peak areas recorded at 254 nm measured against total
absorbance. Absolute quantification of peaks (mass bal-
ance) could not be measured, due to lack of analytical
standards. Relative abundances between classes of mole-
cules were calculated however, using integral values mea-
sured at 254 nm, while specific wavelengths were used to
compare individual compounds within a class; 520, 360,
and 280 nm for anthocyanins, flavonols and phenolics,
respectively (Table 3, peak identities). The primary antho-
cyanins present were peonidin-3-O-galactoside (peak 28,
43% abundance), cyanidin-3-O-galactoside (peak 24, 18%
abundance) and peonidin-3-O-arabinoside (peak 31, 15%






























fraction FC111, displaying separation of 44 constituents.
Alpha numeric labels refer to peaks discussed in the main text, and
Table 3 Laboratory scale cranberry fraction FC111 constituents separated and characterized by HPLC-DAD-MS.
Peak tR (min)
a λmax (nm)b MW (Da)c Putative identification Relative abundanced
1a,b 4.8 192 quinic acid
Iridoids
2a,b 6.5 235 390 monotropein 18.5 ± 0.78%
3 7.3 235 392 6,7-dihydromonotropein 26.8 ± 0.07%
16b 14.4 235 416 unknown monotropein derivative 54.8 ± 0.99%
Total (vs. A254 nm) 22 %
Monophenolic acids
4 8.7 280 220 unknown benzoic acid derivative 3.1 ± 0.51%
5 8.9 280 unknown benzoic acid derivative 0.52 ± 0.06%
6 9.7 290 162 unknown benzoic acid derivative 0.78 ± 0.10%
7 9.8 290 unknown benzoic acid derivative 1.18 ± 0.11%
8 10.4 275 316 dihydroxybenzoic acid glycoside 3.45 ± 0.29%
9a,b 11.6 285, 320 342 caffeic acid glycoside 3.06 ± 0.45%
10 12.0 275 300 hydroxybenzoic acid glycoside 0.72 ± 0.16%
11 12.3 295, 305 326 coumaric acid glycoside isomer 1 14.04 ± 0.49%
12 12.4 275 238 unknown benzoic acid derivative 1.45 ± 0.049%
13 13.6 315 326 coumaric acid glycoside isomer 2 15.1 ± 0.40%
14 13.8 285, 310 326 coumaric acid glycoside isomer 3 16.1 ± 0.56%
15 14.1 295, 325 unknown hydroxycinnamic acid 7.22 ± 0.092%
16a 14.4 280 284 benzoyl-glycoside 5.44 ± 0.89%
17 14.7 285, 330 356 ferulic acid-glycoside 5.59 ± 0.21%
18 15.0 275 unknown benzoic acid derivative 13.24 ± 0.13%
19 15.3 280, 330 386 sinapinic acid-glycoside 7.47 ± 0.28%
20a,b 16.3 280 unknown benzoic acid derivative 1.50 ± 0.69%
Total (vs. A254 nm) 9%
Anthocyanins
21 16.8 525 465 delphinidin-3-O-galactoside 0.40 ± 0.00%
24 18.0 518 449 cyanidin-3-O-galactoside 18.4 ± 0.01%
25 18.2 525 435 delphinidin-3-O-arabinoside 0.60 ± 0.03%
26 19.0 515 433 pelargonidin-3-O-galactoside 0.28 ± 0.00%
27 19.3 520 419 cyanidin-3-O-arabinoside 11.2 ± 0.00%
28 19.8 520 463 peonidin-3-O-galactoside 43.3 ± 0.03%
29 20.4 524 493 malvidin-3-O-galactoside 7.64 ± 0.00%
31 21.1 521 433 peonidin-3-O-arabinoside 15.5 ± 0.01%
33 21.6 530 463 malvidin-3-O-arabinoside 1.79 ± 0.00%
Total (vs. A254 nm) 40%
Flavonols
30 20.5 370 450 myricetin-3-O-arabinoside 4.05 ± 0.34%
32 21.3 360 464 quercetin-3-O-galactoside 50.2 ± 0.11%
34 22.0 354 434 quercetin-3-O-xyloside 7.71 ± 0.00%
35 22.3 352 434 quercetin-3-O-arabinopyranoside 3.72 ± 0.02%
36 22.8 354 434 quercetin-3-O-arabinofuranside 13.65 ± 0.12%
37 23.3 352 448 quercetin-3-O-rhamnoside 2.87 ± 0.01%
38 23.6 356 478 isorhamnetin-3-O-galactoside 5.31 ± 0.04%
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Table 3 Laboratory scale cranberry fraction FC111 constituents separated and characterized by HPLC-DAD-MS.
(Continued)
39 24.0 360 508 syringetin-3-O-galactoside 4.70 ± 0.05%
40 24.7 360 unknown flavonol derivative 0.46 ± 0.02%
41 25.0 355 448 isorhamnetin-3-O-arabinoside 1.55 ± 0.01%
42a,b 25.6 355 610 quercetin-3-O-(6”coumaroyl)-galactoside 2.27 ± 0.04%
43 26.1 355 478 syringetin-3-O-arabinoside 2.04 ± 0.04%
44 27.5 356 568 quercetin-3-O-(6” benzoyl)-galactoside 1.48 ± 0.02%
Total (vs. A254 nm) 25%
a tR , retention time of peak (measured in minutes).
b λmax, refers to characteristic UV–VIS absorption maxima (nm) pertinent to identification.
c MW, molecular weight (measured in Daltons).
d Relative abundance reported as percentage with associated standard deviation (based on two separate HPLC runs); iridoids calculated vs. 254 nm; monophenolic
acids calculated vs. 280 nm; anthocyanins calculated vs. 520 nm; flavonols calculated vs. 360 nm.
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The outbreak of multidrug resistant bacteria arose from
several factors, including the lack of novelty in the pipeline
of drug discoveries since the 1980s, and the large and non-
adequate administration of antibiotics [7,36]. To eradicate
this problem, explorations of new sources of antimicrobial
compounds, and/or finding ways to strengthen the action
of well-known antibiotics are needed [31,37]. For many de-
cades, cranberry juice and extracts have been studied for
their antimicrobial potential against bacterial pathogens.
Cranberry constituents are known to exert anti-adhesion
and antimicrobial activities against several pathogenic bac-
teria and have been suggested to prevent urinary tract in-
fections caused by uropathogenic P-type Escherichia coli
[38-40]. However, the mechanisms supporting the diverse
effects of cranberry on microbes are poorly understood. In
this study, we produced cranberry extracts by mechanical
and ethanol extraction, investigated the antibacterial
modes of action of these extracts by transcriptional and
macromolecular biosynthesis analyses, and assessed their
in vitro and in vivo bactericidal activities.
In an attempt to investigate the mode of action of the
cranberry product NC90, we initiated the study by
performing an exploratory transcriptional analysis by
microarray, which yielded the identification of several bac-
terial genes known to be up-regulated in the presence of
cell-wall acting antibiotics, such as oxacillin, vancomycin
and daptomycin [29,30,41]. Also, the cell wall stress
stimulon we observed correlated well to the list of VraS/R-
regulated genes known to be up-regulated in response to
the inhibition of cell wall biosynthesis [42], as reported in
Table 1. Interestingly, the cranberry PC extract FC111
showed a slightly lower MIC than the commercial prepar-
ation NC90 against S. aureus, indicating enrichment in
some antibacterial compounds in FC111. In addition, qPCR
analysis of key cell wall stress markers (vraR/S, sgtB,
msrA, murZ) revealed similar gene expression modu-
lations by both NC90 and the fraction FC111,indicating that the growth inhibitory compounds
remaining in FC111 should be responsible for the cell wall
stress observed following exposure of S. aureus to this
extract.
Although oxacillin, vancomycin and daptomycin dis-
rupt cell wall peptidoglycan synthesis, these antibiotics
act in different ways [29,43]. In the present study, it was
interesting to observe that NC90 and FC111 also modu-
lated the expression of lytM and the mntABC operon
reacting to membrane depolarization, as distinctively
reported for daptomycin by Muthaiyan et al. [29]. This
may indicate that NC90 and the cranberry extract FC111
induce S. aureus membrane depolarization, as that ob-
served after exposure to daptomycin. The gene modula-
tions induced by cranberry also support the S. aureus cell
disruption reported by Wu et al. [20], while, scanning
electron microscopy of MRSA after treatment with cran-
berry proanthocyanidins induced negligible effect on cell
morphology [44].
The action of our cranberry extract on cell wall biosyn-
thesis was also confirmed by macromolecular biosynthesis
assays in which incorporation D-Ala into cell wall mate-
rials was most affected. Hence, it was therefore tempting
to conduct synergy assays with other cell-wall active anti-
biotics. Because β-lactams are widely used in human and
veterinary medicine and because their activity is often im-
paired by bacterial mechanisms of resistance such as the
presence of β-lactamases or the mecA gene in MRSA
strains, we estimated that such a class of antibiotic com-
pounds may greatly benefit from the action of cranberry
in a variety of clinical applications. Our results showed
that the combination of FC111 and amoxicillin or oxacil-
lin used at sub-MICs, is highly bactericidal against either
β-lactam-susceptible or -resistant MRSA strains. More-
over, this synergy was proven effective in a murine model
of S. aureus-induced mastitis.
Resistance is part of the microbial evolution process and
the use of antibiotics in human or animals applies a
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deed report the presence of multi-antibiotic-resistant bac-
teria in animal food production [45,46]. In order to reduce
antibiotic use, which could help break down emergence of
antibiotic resistance in conventional and organic animal
production, several alternatives to antibiotics have been in-
vestigated although none of these alternatives was proven
to be as efficient as antibiotics [47,48]. We previously sug-
gested that cranberry fruit derivatives could be developed
to improve health and on-farm food safety while reducing
the use of antibiotics as growth promoters [19]. It was re-
cently suggested that fruit pomace can be utilized as a good
source of inexpensive antioxidants for improving human
health and reducing the risks of some chronic diseases
[49]. Recently, we showed that our FC111 fraction from
cranberry pomace (press cake) is an excellent natural
polyphenolics product with increased antioxidant and
vasorelaxant benefits [17]. In the present study, we demon-
strated that this FC111 fraction may be developed as a vi-
able alternative to traditional antibiotics or at least to
significantly potentiate their activities against multidrug re-
sistant bacteria such as MRSA, and thus, to significantly
reduce the amounts of antibiotics required.
The cranberry fruit is rich in polyphenols, specifically
anthocyanins, flavonols and flavan3-ols, which often form
oligomeric and polymeric structures, along with lesser
amounts of benzoic acid derivatives. These natural com-
pounds in cranberry are often collectively referred to as
tannins, which are found in abundance among many
plants including berries, leaves, bark and roots. Tannins
have many biological activities and flavonoids, including
anthocyanins and proanthocyanidins, are believed to be
the major antimicrobial components [50]. Here, the rela-
tive abundances of constituents from fraction FC111 are
described in Table 3. The primary anthocyanins present
were peonidin-3-O-galactoside, cyanidin-3-O-galactoside
and peonidin-3-O-arabinoside. Malvidin-3-O-galacto-
side and 3-O-arabinoside were also present, consist-
ent with previously reported literature for both fresh
cranberry fruit and juice extracts [33,34]. The domin-
ant flavonol was quercetin-3-O-galactoside (peak 32,
50% abundance), followed by three different quercetin-3-
O-pentosides (peaks 34, 35, 36), totaling 25% abundance).
While commercial standards were not available for
the absolute confirmation of these pentosides, they
have been tentatively identified as quercetin-3-O-xyloside,
quercetin-3-O-arabinofuranoside, and querecetin-3-O-ara-
binopyranoside, as previously reported by Borges et al.
[33]. Additionally, numerous early eluting peaks (8–16
min) were detected, with absorption wavelength maxima
characteristic of benzoic acids (λmax ~280 nm) and
hydroxycinnamic acids (λmax ~ 315 nm) (Table 3), also
consistent with previously reported literature [33,34]. Char-
acteristic mass spectra for both parent and fragment ionsindicates a number of these simple phenolic acids are
linked to hexose sugars, but the absolute identity, galactose
versus glucose sugar, or exact O-linkage position could not
be determined using HPLC-MS methods alone.
From our analysis of the constituents of laboratory-
scale fraction FC111, it is unclear, at this point, whether
the observed antibacterial activity stems from iridoids,
phenolics or flavonoid components, with further isola-
tion and characterization remaining an active area of re-
search. However, the mechanisms of action of our FC111
fraction seem not to be related to its acidic constituents,
which negatively impact bacterial proteins and DNA/
RNA syntheses [51]. Bactericidal activity of lab-prepared
cranberry proanthocyanidins has been reported against
MRSA [44]. Proanthocyanidin peaks could not be con-
clusively identified, based upon the HPLC-MS-condi-
tions used. It is possible that the ethanolic PC extraction
may not have been optimal for the solubilization of
proanthocyanidins, which are generally extracted with
more apolar solvents such as acetone. Given their low
(essentially non-abundance) in the extracts studied
herein, proanthocyanidins are not expected to play a
major role in the observed biological effects, unless
extraordinarily active at minute concentrations. Demon-
strating novel antibacterial activity from cranberries not
associated with proanthocyanidin components is espe-
cially exciting, and warrants further investigation.
Conclusions
Our study explored the mechanism of action of cranberry
on S. aureus and revealed an antibacterial action associated
with the disruption of cell wall biosynthesis similar to other
known cell-wall acting antibiotics. Moreover, our results
showed the potential therapeutic use of a combination of
β-lactams and an easily prepared cranberry extract against
S. aureus infections such as bovine mastitis.
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